Literature DB >> 27658423

MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.

Maroof Alam1, Audrey Bouillez1, Ashujit Tagde1, Rehan Ahmad1, Hasan Rajabi1, Takahiro Maeda1, Masayuki Hiraki1, Yozo Suzuki1, Donald Kufe2.   

Abstract

Apical-basal polarity and epithelial integrity are maintained in part by the Crumbs (CRB) complex. The C--terminal subunit of MUC1 (MUC1-C) is a transmembrane protein that is expressed at the apical border of normal epithelial cells and aberrantly at high levels over the entire surface of their transformed counterparts. However, it is not known whether MUC1-C contributes to this loss of polarity that is characteristic of carcinoma cells. Here it is demonstrated that MUC1-C downregulates expression of the Crumbs complex CRB3 protein in triple-negative breast cancer (TNBC) cells. MUC1-C associates with ZEB1 on the CRB3 promoter and represses CRB3 transcription. Notably, CRB3 activates the core kinase cassette of the Hippo pathway, which includes LATS1 and LATS2. In this context, targeting MUC1-C was associated with increased phosphorylation of LATS1, consistent with activation of the Hippo pathway, which is critical for regulating cell contact, tissue repair, proliferation, and apoptosis. Also shown is that MUC1-C--mediated suppression of CRB3 and the Hippo pathway is associated with dephosphorylation and activation of the oncogenic YAP protein. In turn, MUC1-C interacts with YAP, promotes formation of YAP/β-catenin complexes, and induces the WNT target gene MYC. These data support a previously unrecognized pathway in which targeting MUC1-C in TNBC cells (i) induces CRB3 expression, (ii) activates the CRB3-driven Hippo pathway, (iii) inactivates YAP, and thereby (iv) suppresses YAP/β-catenin-mediated induction of MYC expression. IMPLICATIONS: These findings demonstrate a previously unrecognized role for the MUC1-C oncoprotein in the regulation of polarity and the Hippo pathway in breast cancer. Mol Cancer Res; 14(12); 1266-76. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27658423      PMCID: PMC5136335          DOI: 10.1158/1541-7786.MCR-16-0233

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  51 in total

1.  MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells.

Authors:  Hasan Rajabi; Rehan Ahmad; Caining Jin; Michio Kosugi; Maroof Alam; Maya Datt Joshi; Donald Kufe
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 3.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

Review 4.  The emerging roles of YAP and TAZ in cancer.

Authors:  Toshiro Moroishi; Carsten Gram Hansen; Kun-Liang Guan
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

5.  Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.

Authors:  Masanori Hasegawa; Raj Kumar Sinha; Manoj Kumar; Maroof Alam; Li Yin; Deepak Raina; Akriti Kharbanda; Govind Panchamoorthy; Dikshi Gupta; Harpal Singh; Surender Kharbanda; Donald Kufe
Journal:  Clin Cancer Res       Date:  2015-02-23       Impact factor: 12.531

6.  Segregation of receptor and ligand regulates activation of epithelial growth factor receptor.

Authors:  Paola D Vermeer; Lisa A Einwalter; Thomas O Moninger; Tatiana Rokhlina; Jeffrey A Kern; Joseph Zabner; Michael J Welsh
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

Review 7.  MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.

Authors:  D W Kufe
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

8.  Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62.

Authors:  Yumei Leng; Cheng Cao; Jian Ren; Lei Huang; Dongshu Chen; Masaki Ito; Donald Kufe
Journal:  J Biol Chem       Date:  2007-05-11       Impact factor: 5.157

9.  Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.

Authors:  Deepak Raina; Praveen Agarwal; James Lee; Ajit Bharti; C James McKnight; Pankaj Sharma; Surender Kharbanda; Donald Kufe
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

10.  The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity.

Authors:  K Aigner; B Dampier; L Descovich; M Mikula; A Sultan; M Schreiber; W Mikulits; T Brabletz; D Strand; P Obrist; W Sommergruber; N Schweifer; A Wernitznig; H Beug; R Foisner; A Eger
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

View more
  25 in total

Review 1.  MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Authors:  Donald W Kufe
Journal:  Carcinogenesis       Date:  2020-09-24       Impact factor: 4.944

2.  MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

Authors:  Tsuyoshi Hata; Hasan Rajabi; Hidekazu Takahashi; Yota Yasumizu; Wei Li; Caining Jin; Mark D Long; Qiang Hu; Song Liu; Atsushi Fushimi; Nami Yamashita; Ling Kui; Deli Hong; Masaaki Yamamoto; Masaaki Miyo; Masayuki Hiraki; Takahiro Maeda; Yozo Suzuki; Mehmet K Samur; Donald Kufe
Journal:  Cancer Res       Date:  2019-09-13       Impact factor: 12.701

3.  A CRISPR Screen Identifies the Cell Polarity Determinant Crumbs 3 as an Adeno-associated Virus Restriction Factor in Hepatocytes.

Authors:  Victoria J Madigan; Tyne O Tyson; Julianne A Yuziuk; Minakshi Pillai; Sven Moller-Tank; Aravind Asokan
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

4.  MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.

Authors:  Takahiro Maeda; Masayuki Hiraki; Caining Jin; Hasan Rajabi; Ashujit Tagde; Maroof Alam; Audrey Bouillez; Xiufeng Hu; Yozo Suzuki; Masaaki Miyo; Tsuyoshi Hata; Kunihiko Hinohara; Donald Kufe
Journal:  Cancer Res       Date:  2017-12-20       Impact factor: 12.701

5.  Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.

Authors:  Tsuyoshi Hata; Hasan Rajabi; Masaaki Yamamoto; Caining Jin; Rehan Ahmad; Yan Zhang; Ling Kui; Wei Li; Yota Yasumizu; Deli Hong; Masaaki Miyo; Masayuki Hiraki; Takahiro Maeda; Yozo Suzuki; Hidekazu Takahashi; Mehmet Samur; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2019-07-15       Impact factor: 6.261

Review 6.  MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.

Authors:  Hasan Rajabi; Donald Kufe
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-14       Impact factor: 10.680

Review 7.  MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.

Authors:  Hasan Rajabi; Masayuki Hiraki; Donald Kufe
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

8.  MUC1-C activates BMI1 in human cancer cells.

Authors:  M Hiraki; T Maeda; A Bouillez; M Alam; A Tagde; K Hinohara; Y Suzuki; T Markert; M Miyo; K Komura; R Ahmad; H Rajabi; D Kufe
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

Review 9.  Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

Authors:  Qinqin Li; Zhenghuan Rao; Yanlin Wang; Lei Zhang; Jing Chen; Runlan Wan; Alexander Tobias Teichmann
Journal:  Cancer Cell Int       Date:  2021-06-10       Impact factor: 5.722

Review 10.  MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.

Authors:  Wenqing Chen; Zhu Zhang; Shiqing Zhang; Peili Zhu; Joshua Ka-Shun Ko; Ken Kin-Lam Yung
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.